CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for OKYO Pharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

OKYO Pharma Ltd
Floor 4, 14/15 Conduit St
Phone: +44 2074952379p:+44 2074952379 LONDON, W1S 2XJ  United Kingdom Ticker: OKYOOKYO
Business Summary
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20253/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Gabriele M.Cerrone 53 1/1/2021 1/1/2021
Chief Executive Officer, Executive Director Gary S.Jacob 77 1/1/2021 1/1/2021
Chief Financial Officer KeerenShah 48 8/1/2020 8/1/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
EMMLF
OK11
OKYO

General Information
Number of Employees: 4 (As of 3/31/2025)
Outstanding Shares: 37,610,676 (As of 7/3/2025)
Stock Exchange: NASD
Email Address: info@okyopharma.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 22, 2025